
Melanocortin receptors are a family of five G protein-coupled receptors — MC1R, MC2R, MC3R, MC4R and MC5R — built on the same seven-transmembrane, rhodopsin-family scaffold and activated by peptide agonists derived from the proopiomelanocortin (POMC) precursor.[1][2] MC1R is a pigment-regulating receptor on melanocytes, with variants associated with human pigment phenotype.[3][4] MC3R and MC4R have distinct roles in energy balance: mouse Mc3r deletion changes fat and lean mass, human MC3R loss-of-function variants affect growth and pubertal timing, and human MC4R deficiency is associated with hyperphagia and severe early-onset obesity.[5][6][7]
All five receptors share canonical Gαs signalling, which activates adenylyl cyclase and raises intracellular cyclic AMP (cAMP), although other pathways operate in some cellular contexts. Endogenous inhibitory proteins distinguish this system: agouti-related protein (AgRP) acts at MC3R and MC4R as an inverse agonist, while agouti signalling peptide (ASIP) competes with melanocortin agonists at MC1R and MC4R.[8]
The Five Receptors and Their Ligand Logic
The receptors differ in where they are expressed and how they respond to ligands. MC2R is the ligand-specific outlier: it responds to ACTH alone.[1] The locations below are representative, not exclusive; receptor expression extends beyond the familiar division between skin, adrenal gland, brain and exocrine glands.[8]
| Receptor | Representative expression sites | Ligand or coupling note |
|---|---|---|
| MC1R | Melanocyte plasma membrane; expression also reported in periaqueductal gray matter, astrocytes and leukocytes.[3] | Gαs → adenylyl cyclase → cAMP.[3] |
| MC2R | Adrenal gland, where it is required for steroidogenesis.[8] | ACTH-specific;[1] canonical Gαs/cAMP signalling.[8] |
| MC3R | Hypothalamus;[5] kidney.[9] | POMC-derived agonists; Gαs/cAMP, with Gαi and/or Gαq/11 reported in some contexts.[8] |
| MC4R | Central nervous system.[8] | Gs coupling demonstrated structurally and through cAMP assays;[10] Gq signalling also reported.[9] |
| MC5R | Exocrine glands, brain, adipose tissue and skeletal muscle.[11] | Gαs/cAMP and Gαq/Ca2+ signalling.[11] |
The common cAMP pathway does not mean every receptor produces the same cellular response. Gαs activates adenylyl cyclase, which converts ATP to cAMP, but MC3R and MC4R can also interact with other G-protein subunits. In neuronal cell culture, α-MSH activation of MC4R in paraventricular nucleus neurons has been reported to engage Gαq/11 rather than Gαs.[8] MC5R can additionally engage PI3K–ERK1/2 signalling, while MC2R depends on the accessory protein MRAP for trafficking to the cell surface.[11] Receptor identity, cellular location and signalling partners therefore all matter to its function.
MC1R: Pigmentation, cAMP, and Human Variants

MC1R — also called the melanocyte-stimulating hormone receptor — connects an extracellular melanocortin signal to pigment production within melanocytes. Receptor activation engages Gαs and elevates intracellular cAMP through adenylyl cyclase.[3] MSH acting through MC1R increases synthesis of eumelanin, the black-brown pigment, while the agouti gene product opposes this action. The balance between eumelanin and red phaeomelanin contributes to the visible pigment phenotype.[4]
Human genetics connects this receptor biology to natural variation. A 1995 association study identified MC1R sequence variants associated with red hair and fair skin, supporting MC1R as a control point in human pigmentation.[4]
The distinction between the pigment and the receptor also matters. Eumelanin and phaeomelanin are the pigment products, whereas MC1R is a membrane signalling protein that helps regulate their balance. A change in the receptor can therefore affect a downstream cellular phenotype without changing the identity of the pigment molecules themselves.[3][4]
MC3R and MC4R: Hypothalamic Control of Energy Balance

Energy stored in the body is signalled to the brain, which uses that information to adjust behaviour, growth, nutrient partitioning and development.[6] Leptin, released by adipocytes, activates POMC neurons in the arcuate nucleus of the hypothalamus. Those neurons project to the paraventricular nucleus, lateral hypothalamus and dorsomedial hypothalamus, where they release α-MSH onto MC4R-bearing neurons. Leptin also inhibits AgRP/NPY neurons, the opposing arm of the circuit.[9] MC4R helps control appetite, food intake and energy expenditure through this central melanocortin system.[6]
The leptin–POMC route is not the entire leptin response. In mouse experiments, deleting leptin receptors specifically from POMC neurons caused only mild obesity, whereas deleting neuronal leptin receptors more broadly produced hyperphagia and severe obesity. This contrast indicates that leptin acts through additional neuronal populations rather than through a single linear relay.[9]
MC3R is not simply a backup for MC4R. Mice lacking Mc3r, examined at four to six months, had increased fat mass, reduced lean mass and higher feed efficiency than wild-type littermates — despite eating less and maintaining normal metabolic rates. They were hyperleptinaemic, males developed mild hyperinsulinaemia, and corticosterone and total thyroxine were not significantly altered. Mice lacking both Mc3r and Mc4r were significantly heavier than mice lacking Mc4r alone, demonstrating non-redundant roles in mouse energy homeostasis.[5]
Human MC3R genetics highlights developmental timing and nutrient partitioning. People carrying loss-of-function variants, including a rare homozygote, had later onset of puberty, reduced linear growth, lower lean mass and lower circulating IGF1. Mice lacking Mc3r also showed delayed maturation.[6] These findings distinguish MC3R-associated growth and developmental phenotypes from the prominent food-intake phenotype of MC4R deficiency.
MC4R deficiency is described as the commonest monogenic form of obesity in a 2003 human genetics study. Sequencing MC4R in 500 probands with severe childhood obesity identified mutations in 29 of them (5.8%) — 23 heterozygous and 6 homozygous. Carriers had severe obesity, increased lean mass, increased linear growth, hyperphagia and severe hyperinsulinaemia; homozygotes were more severely affected than heterozygotes.[7] The 5.8% figure describes this selected severe-childhood-obesity cohort, not the general population.
Variants retaining residual signalling capacity were associated with a milder phenotype, and inheritance in the study was codominant. The relationship between mutant-receptor signalling and energy intake connects receptor function to eating behaviour in humans.[7] Mouse knockouts and inherited human variants reveal different aspects of receptor function; neither establishes the effects of altering MC3R or MC4R activity in an adult.
Inside the MC4R Binding Pocket
A 2024 cryo-EM structure of human MC4R bound to the nanobody agonist pN162 and Gs, at a nominal resolution of 3.41 Å, shows activation hallmarks also observed with peptide and small-molecule agonists. Transmembrane helix 6 moves outward by 13.3 Å at the measured residue, opening the intracellular region for G-protein engagement. The CWxP toggle-switch motif and MIF triad rearrange, while the NPxxY motif and the DRY-motif arginine R147 adopt active-state positions.[10] These coordinated changes connect extracellular ligand binding to an intracellular signalling partner.
The orthosteric pocket — the site occupied by the studied agonist — is unusually open because extracellular loop 2 is only one residue long. A calcium ion occupies the orthosteric site as a cofactor, coordinated by E100, D122 and D126 together with backbone contacts from peptide ligands in previously described structures.[10] Ligand recognition therefore involves both the receptor’s amino-acid contacts and its local ionic environment.
Shared receptor architecture does not imply identical ligand selectivity. In recombinant-cell assays, pN162 induced detectable Gs-mediated signalling only at MC4R among the receptors tested, whereas α-MSH activated multiple melanocortin subtypes. At MC4R, pN162 also recruited β-arrestin2 and activated a Gq-associated readout.[10] These are structural and in vitro pharmacology findings, not measurements of whole-organism physiology. They show how a receptor with a familiar Gs/cAMP pathway can recognize ligands selectively while engaging more than one intracellular signalling route.
References
- Melanocortin receptor — Wikipedia
- Studies on the physiological functions of the melanocortin system (Cone, Endocr Rev 2006; abstract)
- Melanocortin 1 receptor — Wikipedia
- Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans (Valverde et al., Nat Genet 1995; abstract)
- Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass (Chen et al., Nat Genet 2000; abstract)
- MC3R links nutritional state to childhood growth and the timing of puberty (Lam et al., Nature 2021; abstract)
- Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene (Farooqi et al., N Engl J Med 2003; abstract)
- The Multifaceted Melanocortin Receptors (Endocrinology 2022)
- Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system (Clin Sci 2026)
- Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist (Nat Commun 2024)
- Melanocortin-5 Receptor: Pharmacology and Its Regulation of Energy Metabolism (2022)
Related research: What Is Melanotan I: Afamelanotide and MC1R Research; What Is PT-141: Bremelanotide and Melanocortin Research; Melanotan I.
Research Use Only: For laboratory research and analytical education only. This article is not a validated experimental protocol or medical or veterinary advice. Research materials are not for administration to humans or animals.